Diagnosis and treatment of nonalcoholic fatty liver disease in patients with metabolic syndrome: potential of cardiac and antidiabetic medications

Abstract

According to recent guidelines of AASLD, AGA and ACG, NAFLD is a liver disease accompanied by the accumulation of fatty acid content greater than 5% of hepatocytes weight, absence of substantial alcohol consumption (20 g per day for men, 10 g per day for women), absence of hepatitis viruses and other specific causes of liver disease.

Keywords

• нажбп
• метаболический синдром
• ожирение
• орлистат
• аторвастатин
• липтонорм
• nafld
• metabolic syndrome
• obesity
• orlistat
• atorvastatin
• liptonorm